Background The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary fi ndings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up.
Introduction
External beam radiotherapy is one of the standard curative options for men with localised prostate cancer and is particularly appropriate for men with intermediate-risk or high-risk disease.
1,2 Improved radiotherapy techniques, such as conformal radiotherapy, allow high treatment doses to be given safely 3, 4 and several phase 3 randomised controlled trials of dose escalation have reported improved biochemical progression-free survival. [5] [6] [7] [8] [9] [10] The Medical Research Council (MRC) RT01 trial is the largest of these trials to have reported results, and since its initial report of results dose-escalated conformal radiotherapy has been the standard of care in the UK since 2008. 1 The trial mandated the use of short-course neoadjuvant androgen deprivation therapy (ADT); neoadjuvant ADT has since been shown to improve overall and cancer-specifi c survival in patients with advanced localised disease. [11] [12] [13] [14] The aim of the RT01 trial was to assess the eff ect of dose-escalation on overall survival, biochemical progression-free survival, and toxicity, by comparing doses of 74 Gy and 64 Gy delivered by use of conformal radiotherapy techniques. 64 Gy in 32 fractions was chosen as the radiotherapy schedule for the control group in our randomised trial, because that was the standard dose at the time the trial was designed. We initially reported fi ndings of the trial with a 5-year median followup and now update these results with a median follow-up of 10 years, because the target number of deaths for analysis of overall survival has been reached. Treatmentrelated side-eff ects have been reported previously. 7, 15, 16 
Methods

Study design and participants
RT01 was a phase 3, open-label, international, randomised controlled trial comparing dose-escalated conformal radiotherapy with control-dose conformal radiotherapy. It was preceded by a pilot study at the Royal Marsden Hospital. 5 Patients were registered, initiated on neoadjuvant ADT, and then randomly assigned to receive either control or escalated radiotherapy using conformal radiotherapy techniques. Men 18 years or older with histologically confi rmed T1b-T3a, N0, M0 prostate cancer and prostate-specifi c antigen (PSA) of less than 50 ng per mL, with no contraindications for radical radiotherapy were included in the trial. All patients gave written informed consent. The trial was overseen by a trial management group and reviewed on three occasions by an independent data-monitoring committee. No formal stopping rules were specifi ed. At each review, the Data Monitoring and Ethics Committee re com mended that the trial could continue. This study was done in compliance with the Declaration of Helsinki, and the protocol was approved by the appropriate Research Ethics Committees.
Randomisation and masking
Consenting patients were randomly assigned in a 1:1 ratio to control or escalated-dose conformal radiotherapy centrally at the MRC clinical trials unit (CTU) using a computer-based minimisation algorithm, stratifying for risk of seminal vesicle invasion and centre. Sites phoned MRC CTU to randomise patients. Neither participants nor investigators were masked to the allocated treatment because blinding was not practicable. The random allocation list was created by the MRC CTU.
Procedures
As reported previously, androgen deprivation was achieved using injections of luteinising-hormonereleasing hormone agonists every 4 weeks and was accompanied by antiandrogen therapy to prevent fl are events. 7 Neoadjuvant ADT was given for 3-6 months before commencement of conformal radiotherapy and continued until the end of conformal radiotherapy.
Men were randomised to receive either a control-dose schedule (64 Gy in 32 fractions; control group) schedule, or an escalated-dose schedule (74 Gy in 37 fractions). All radiotherapy treatments used three-dimensional conformal techniques as previously described. 7, 11, 17 The radiotherapy phase 1 target volume included the prostate and all or part of the seminal vesicles, depending on the 18 All patients were treated to a dose of 64 Gy in 32 fractions over 6·5 weeks using a standard three-fi eld plan (anterior fi eld and left and right lateral or posterior oblique fi elds) with a 1·0 cm margin. Patients randomised to the escalated-dose group had a phase 2 boost to the prostate alone using a six-fi eld technique (left and right anterior oblique, left and right posterior oblique, and left and right lateral fi elds) with no margin added. The boost radiotherapy followed the phase 1 treatment. All doses were prescribed to the isocentre. Beam shaping was with multileaf collimators or customised shaped blocks and treatment was delivered with 6-10 MV photons. No dose constraints for normal tissues were specifi ed. Verifi cation was with daily and then weekly port fi lms and images.
Men were followed-up throughout radiotherapy at 6 monthly intervals up to 2 years, and annually thereafter. Acute and late treatment-related side-eff ects were collected using Radiation Therapy Oncology Group 19 and Late Eff ects of Normal Tissues-Subjective Objective Management Analytic scales 20 and timed from the start of radiotherapy. Disease assessments were PSA, digital rectal examination, and symptoms. Technetium-99m bone scans, CT, or MRI were done as clinically indicated. The design, objectives, eligibility criteria for patients, treatment methods, and statistical considerations are detailed elsewhere.
7,17
Outcomes
The coprimary outcome measures were overall survival and biochemical progression-free survival. Overall survival was defi ned as time from randomisation to death from any cause or censoring at date of last contact. Biochemical progression-free survival was defi ned as time from randomisation to biochemical failure, death from prostate cancer, or development of local, nodal, or metastatic disease, whichever occurred fi rst. Additional outcome measures were biochemical failure (an increase in PSA concentration to 50% above nadir and above 2 ng/mL 6 months or more after the start of radiotherapy); progression-free survival (excluding PSA failure); initiation of long-term salvage ADT; development of metastases; death from prostate cancer; and metastasesfree survival (time to development of any metastases or death from prostate cancer). Cause of death was reviewed by pairs of clinicians from a panel of fi ve individuals who were masked to treatment allocation.
The original protocol specifi ed fi ve primary outcome measures (biochemical progression-free survival [named as "biochemical control" in the protocol, freedom from local progression, metastases free survival, overall survival, and late toxicity); with sample size calculations included for local control and overall survival. During the course of the trial, the Trial Management Group, Independent Data Monitoring Committee, and Trial Steering Committee agreed from external evidence that biochemical progression-free survival was a more important outcome measure than local control. Therefore, the trigger for intermediate and long-term analyses has been biochemical progression-free survival and overall survival. All outcome measures are reported.
Statistical analysis
We estimated that inclusion of about 800 patients would meet the targets for the numbers of patients in the subgroups at low-risk and intermediate-risk of seminal vesicle involvement. 17 We assumed that survival at 5 years would be 50% in patients in the control group, and the trial aimed to achieve a 15% increase in survival at 5 years in the escalated-dose group. Assuming proportional hazards, this improvement corresponds to a hazard ratio (HR) of 0·62. With 90% power and a 5% two-sided signifi cance level, we established that about 194 deaths were needed for this analysis of overall survival.
We did all analyses on an intention-to-treat basis, with patients analysed according to allocated treatment group. We used a two-sided 5% signifi cance level for all analyses. All analysed outcome measures are presented in this report.
We used standard survival analysis methods to investigate time from randomisation to the fi rst reported event for each outcome measure, except for time to death from prostate cancer. Patients who have not yet reported the relevant event are censored at the date of last contact. Median follow-up time was established with the reverse Kaplan-Meier method. The assumption of proportionality of hazards was tested. Hazard ratios (HR) were estimated with Cox models, adjusted for seminal vesicle risk group. 18 We applied the restricted mean survival time method to overall survival and biochemical progressionfree survival, as an additional method of estimating diff erence between the treatments, with the restriction time being 10 years. We used fl exible parametric modelling to estimate restricted mean survival time. All comparisons are expressed relative to the control group; therefore, an HR of less than 1·0 indicates a decreased risk in the escalated-dose group.
We did a competing-risk analysis for prostate cancer death because the number of deaths from causes other than prostate cancer exceeded the prespecifi ed level of 20%. For this analysis, time to prostate cancer death is presented with cumulative incidence function rather than survival function; sub-HR is presented with 95% CI and p value. We used the method of Fine and Gray 21 to estimate sub-HR. Cause-specifi c HRs are presented for both prostate cancer and non-prostate-cancer deaths.
We did pre-planned, exploratory subgroup analyses to examine consistency of eff ect across seminal vesicle risk group (low vs moderate) and National Comprehensive Cancer Network (NCCN) risk group (low vs intermediate vs high). 2 This analysis uses χ² tests for heterogeneity of interaction or trend when appropriate, and examines overall survival and biochemical progression-free survival. A health economic analysis is planned.
We used Stata (version 12.1) for analyses. This trial is registered, number ISRCTN47772397. 
HR (95% CI)
Favours escalated-dose Favours control 1·0 0·5 2·0
Role of the funding source
The trial was sponsored by UK Medical Research Council and conducted by the MRC Clinical Trials Unit (from August, 2013, part of University College London). MRC employees were central to the conduct of the trial and the development of this report. The sponsor of the trial had no role in trial design, data analysis, or data interpretation. MRS and GJ had access to raw data. MRS had access to all data in the trial and had fi nal responsibility for the decision to submit for publication.
Results
Between Jan 7, 1998, and Dec 20, 2001 , 862 men were registered and 843 subsequently randomised: 422 to the escalated-dose group and 421 to the control group (fi gure 1). As of Aug 2, 2011, 236 deaths had been reported, 118 in each group, triggering the overall survival analysis. There was no diff erence in 10 year overall survival between groups: 10 year overall survival was 71% (95% CI 66-75) in both groups (HR 0·99, 95% CI 0·77-1·28, p=0·96, fi gure 2). Mean overall survival, using the fl exible parametric model and when restricted to 10 years, was 9·30 years (95% CI 9·08-9·52) for the control group and 9·28 years (9·06-9·50) for the escalated-dose group. There was no evidence of a diff erence between restricted mean survival: -0·02 years (95% CI -0·34 to 0·29; p=0·88).
For patients who had not yet reported a biochemical progression event, adherence to PSA testing was 90% complete at 5 years and 76% complete at 10 years. Adherence patterns were much the same in the two randomised groups (appendix). 391 biochemical progression events occurred: 221 (57%) in the control group and 170 (43%) in the escalated-dose group. Biochemical progression-free survival was better in the escalated-dose group, being 43% at 10 years (95% CI 38-48) in the control group and 55% (50-61) in the escalated-dose group (HR 0·69, 95% CI 0·56-0·84; p=0·0003, fi gure 2). Mean biochemical progressionfree survival, when time of analysis was restricted to 10 years, was 7·33 years (95% CI 6·87-7·80) in the control group and 8·01 years (7·60-8·40) in the escalated-dose group, leading to an improvement in restricted mean survival of 0·69 years with escalateddose radiotherapy (95% CI 0·08-1·30; p=0·03). This fi nding represents a relative improvement of about 10% in the escalated-dose group compared to the control group. The assumption of proportional hazards was tested and there was no evidence of non-proportionality for any of the outcome measures; therefore, HR is an appropriate summary measure. HR=hazard ratio. ADT=androgen deprivation therapy. PFS=progression-free survival. MFS=metastases-free survival. *Defi ned as PSA failure or PFS event. †Defi ned as PSA greater than 2 ng/mL, 6 months or more after commencement of radiotherapy and PSA rising from nadir concentration by 50% or more. ‡Defi ned as local progression, lymph node, bone or other metastases, prostate-cancer-related death, or restart of ADT. §Defi ned as bone or other metastases or prostate-cancer-related death. ¶Sub-HR. ||Cause-specifi c HR. Figure 3 shows subgroup analyses by seminal vesicle involvement and NCCN risk group. We identifi ed no diff erence in the treatment eff ect across these subgroups in overall survival and biochemical progression-free survival. Progression-free survival, biochemical failure, and delayed commencement of salvage ADT were all signifi cantly better in the escalated-dose group compared to the control group (table 2, fi gure 4). Of patients who had biochemical progression, a lower proportion (67 [30%] of 221 patients) in the control group had metastases, or died from prostate cancer compared to the escalated-dose group (65 [38%] of 170 patients). Notably, of the 391 patients who developed PSA failure or progressive disease, only 220 (56%) reported commencing long-term salvage ADT (123 in the control group, 97 in the escalated-dose group). Of 268 men who had clinical evidence of progressive disease, 132 (49%) developed metastases or died from prostate cancer (67 in the control group, 65 in the escalated-dose group).
According to the central, blinded review of deaths, 91 of 236 (39%) deaths were from prostate cancer (44 in the control group, 47 in the escalated-dose group), 132 (56%) were from other causes (68 in the control group vs 64 in the escalated-dose group), and for 13 (6%) patients there were insuffi cient data for the reviewers to assign cause of death (six control vs seven escalated dose): for ten, the investigator defi ned causality as not prostate cancer (which was accepted), and for the other three, no evidence of recurrent prostate cancer had been recorded. Therefore, 91 patients were deemed to have died from prostate cancer and 145 from other causes. Overall concordance between the investigators and clinical review was good (199 of 236, 84%; κ statistic 0·71).
We did a competing-risk analysis for prostate cancer death because 145 (61%) of 236 deaths were from causes other than prostate cancer, which exceeded the prespecifi ed level of 20%. The competing-risk analysis showed no evidence of a diff erence in death from prostate cancer. The sub-HR for the comparison of cumulative incidences is 1·07 (95% CI 0·71-1·61; p=0·75) in favour of the control group with a cause-specifi c HR for prostate cancer deaths of 1·06 (95% CI 0·70-1·60; p=0·79) and for other deaths of 0·96 (0·69-1·32; p=0·78).
NCCN risk group was available for 90 of the 91 patients who died from prostate cancer. NCCN risk group was clearly related to the probability of dying from prostate cancer. Only one of 160 (1%) men with low-risk disease died from prostate cancer compared with 21 of 311 (7%) with intermediate-risk disease and 68 of 362 (19%) with high-risk disease. As a proportion of total deaths, for lowrisk disease, one (control group) of 20 (5%) were from prostate cancer compared with 21 (nine control vs 12 escalated-dose) of 81 (26%) for intermediate-risk disease and 68 (34 control vs 34 escalated-dose) of 133 (51%) for high-risk disease. We identifi ed no evidence of heterogeneity of eff ect of dose escalation between these subgroups.
Discussion
The previously reported advantage of escalated-dose conformal radiotherapy treatment compared to controldose conformal radiotherapy in biochemical progressionfree survival after a median follow-up of about 5 years was maintained in the present study with more mature data and a median follow-up of 10 years. Using the HR, there was an absolute 13% (95% CI 6-19) increase in biochemical progression-free survival at 10 years from 43%. This improvement in biochemical control of disease has not translated into an advantage for metastases-free survival, prostate-cancer-specifi c survival, or overall survival. We identifi ed no evidence of heterogeneity of treatment eff ect between low, intermediate, and highrisk groups.
We recorded a signifi cant delay in the reported time to initiation of long-term, salvage ADT in the escalated-dose group; using the HR there was an absolute improvement of 7% (95% CI 0-12) at 10 years from 45%. This advantage of reducing or delaying the initiation of long-term ADT, which is associated with well-documented andropausal side-eff ects, 22 must be balanced against the known small increase in bowel side-eff ects from the fi ve extra treatments in the escalated-dose group, which we and others have reported. 5, 6, 8, 10, 16, 23 Why has the diff erence in PSA control not translated into an advantage for metastasis-free survival and prostate-cancer-specifi c survival? Several factors might be involved. First, it is likely that there were more indolent recurrences confi ned to the prostate in the control group: a lower proportion of patients in the control group had metastases or died from prostate cancer than those in the escalated-dose group. Moreover, of patients who developed PSA failure or progressive disease, only 56% reported commencing long-term salvage ADT, and only 49% of patients who had clinical evidence of progressive disease developed metastases or died from prostate cancer. We now know that some men with indolent local disease do not necessarily need treatment, for example men with low-risk disease or older than 65 years do not benefi t from radical prostatectomy, 24, 25 and active surveillance has become a standard of care for patients with a favourable outlook. 26 Second, there is a long time from commencement of salvage ADT to death. In an international trial of intermittent or continuous salvage androgen suppression, 22 time from salvage ADT to death was estimated at about 9 years, but with only about 17% of patients dying of prostate cancer after 7 years. In the control group of RT01, 25% of patients had a biochemical progression-free survival event by 2·6 years after randomisation, but it was 5·7 years from randomisation before 25% of patients had reported initiation of salvage ADT; median times for these outcome measures have not been reached. Moreover, our results clearly show that NCCN risk group was related to the probability of dying from prostate cancer.
The lower bound of the 95% CI for overall survival was 0·77, and therefore our results cannot rule out some improvement in overall survival. More prolonged followup might show a diff erence in prostate-cancer mortality. After 14 years of follow-up, the small pilot study (N=126) which recruited before the start of RT01 suggested an overall survival advantage for the escalated-dose group (74 Gy) with HR 0·59, but with only 19 prostate cancer deaths the 95% CIs were wide (0·23-1·49). 5 Our trial was designed in 1997 and launched in 1998 before the Phoenix defi nition 27 for biochemical recurrence became established, but our chosen defi nition of PSA failure with 2 ng/mL has much the same specifi city and sensitivity. 28 Our results are in alignment with reported data from other studies of dose-escalated external beam radiotherapy (table 3) , which have shown absolute advantages in PSA failure-free survival of 6-19% for dose-escalated treatments.
Even in trials with a high proportion of patients with poor prognostic factors and long follow-up, none have yet reported prostate-cancer-specifi c mortality of greater than 15%. When designing the RT01 trial, we anticipated that most patients would die of the disease. However, overall survival was much better than predicted and death from non-prostate-cancer causes was a major competing risk. A meta-analysis with the other randomised trials would provide a larger number of events from patients with high-risk disease to assess the eff ect of dose-escalation on death from prostate cancer.
Our fi ndings draw attention to two issues for future trials. First, prostate-cancer-specifi c survival has become a diffi cult outcome measure for localised prostate cancer trials to report in a reasonable timescale. Survival-based outcome measures must remain of paramount importance, but there are implications for recruiting centres, trials units, and funding bodies in collecting long-term data. The potential value of highquality, electronically linked, routinely collected outcome data needs to be explored. Second, it is particularly important to minimise treatment-related side-eff ects in groups of patients who are expected to live for a long time. We have previously reported our comparative side-eff ect data, which we planned to collect only to 5 years, 7, 15, 16 and a limitation of the present report is that no 10-year patient-reported outcome data are available.
By contrast with the dose-escalation trials, phase 3 studies assessing the addition of neoadjuvant ADT to radical prostate radiotherapy have shown clear evidence of improved overall survival and cause-specifi c survival in meta-analysis. 29, 30 Review of additional trial results [11] [12] [13] [14] shows that survival benefi ts become apparent about 3-5 years after randomisation. One interpretation is that, in addition to short-course ADT having an eff ect on local control of disease, 11 6 months of ADT also has a direct eff ect on eradication of micrometastatic disease. These trials have been in patients given modest doses of radiotherapy by present standards (equivalent to 70 Gy or lower) but large institutional US series have suggested much the same benefi ts of neoadjuvant ADT in patients given doses of 76-81 Gy. 31, 32 What are the relative merits of dose escalation and combined modality treatment with neoadjuvant ADT? Dose escalation leads to excellent local disease control using either external beam radiotherapy or brachytherapy 33 in lower risk disease. In more advanced NCCN intermediate-risk or high-risk localised disease neoadjuvant ADT seems to improve both local control and reduce distant metastases. By use of a biopsy sample obtained 2 years after treatment as a gold standard method 34 to detect local recurrence, a 3-month period of neoadjuvant ADT given with modest-dose or high-dose radiotherapy reduced positive biopsy fi ndings from 46% to 10%. 35 In a preplanned substudy of the RT01 trial, only six (6%) of 97 men in the escalated-dose group who agreed to have a biopsy 2 years after treatment had positive histology (unpublished). The gain of further dose escalation when given with neoadjuvant ADT might therefore be limited. The use of neoadjuvant ADT, however, must be balanced against the usually short-lasting increase in morbidity from
Panel: Research in context
Systematic review Radiotherapy dose is limited by treatment-related side-eff ects. Advancing radiotherapy techniques using conformal radiotherapy had been shown to reduce the occurrence of side-eff ects.
3 Dose-escalation therefore became feasible with the hypothesis that higher radiation doses would lead to improved outcomes. 5, [37] [38] [39] Interpretation As far as we are aware, this study is the largest dose-escalation trial to have reported long-term effi cacy results. Other dose-escalation trials 5, 6, [8] [9] [10] in prostate cancer have shown an improvement in disease outcome assessed by biochemical progression-free survival. However, none of these trials have convincingly shown a positive eff ect on overall or prostate-cancer-specifi c survival after 10 years of follow-up. Dose escalation improves intermediate disease outcomes and reduces the use of salvage hormonal treatment, but at the cost of a modest increase in treatment-related side-eff ects. Further improvements in radiotherapy techniques have been shown to reduce the eff ect of dose-escalation on side-eff ects 4, 40, 41 and should be used to maintain the reported advantages of dose-escalation while minimising treatment sequelae. short-term ADT. 36 Clinical trials that are in progress, including EORTC study 22991 (NCT00021450), will more completely defi ne the role of combined modality treatment and high-dose radiotherapy.
Since we designed our trial using conformal radiotherapy methods, technology advances have led to the widespread introduction of intensity-modulated, image-directed, and image-guided techniques including the combined use of external beam radiotherapy with high-dose or low-dose rate brachytherapy, which have enabled high-dose treat ment to be given with a reduced prevalence of side-eff ects using conventional or hypofractionated schedules (panel). 4, 40, 41 High-quality treatments are essential to maintain the potential advantages of dose-escalated treatment in improving disease control and avoiding salvage therapy, while maintaining low levels of treatmentrelated side-eff ects.
In conclusion, we have shown a clear and maintained advantage in biochemical (PSA) assessment of disease control, which has translated into a modest reduction in salvage ADT, but no evidence of a benefi t in survivalbased outcome measures with a median follow-up of 10 years. These effi cacy data must be weighed against the increase in acute and late toxicities associated with escalated dose.
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